Cargando…
Author Correction: NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
Autores principales: | Gupta, Shilpa, Kamat, Ashish M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608133/ https://www.ncbi.nlm.nih.gov/pubmed/32719534 http://dx.doi.org/10.1038/s41585-020-0361-5 |
Ejemplares similares
-
NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020) -
Author Correction: CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression
por: Saponaro, Miriam, et al.
Publicado: (2023) -
Author Correction: An integrated platinum-nanocarbon electrocatalyst for efficient oxygen reduction
por: Huang, Lei, et al.
Publicado: (2022) -
Author Correction: Myeloperoxidase is not a good biomarker for preeclampsia prediction
por: Rocha-Penha, L., et al.
Publicado: (2018) -
Author Correction: MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma
por: Yerukala Sathipati, Srinivasulu, et al.
Publicado: (2022)